24S-hydroxycholesterol is associated with agitation severity in patients with moderate-to-severe Alzheimer’s disease: Analyses from a clinical trial with nabilone

Manuscript Number: 

19-0202R1

Author(s): 
Ana Andreazza, Sandra E. Black, Damien Gallagher, Nathan Herrmann, Alex Kiss, Krista L. Lanctôt, Myuri Ruthirakuhan, Nicolaas Paul LG Verhoeff

Disclosures

Ana Andreazza

  • Nothing to Disclose

Sandra E. Black

  • Consulting Fees:
    Ad hoc consultancy (<$10,000) Novartis Roche
    Lecture Fees:
    CME Novartis (<$10,000)
    Grants
    • Agency: 
      GE Healthcare
      Dates: 
      2017-Present
    • Agency: 
      Eli Lilly
      Dates: 
      2017-Present
    • Agency: 
      Biogen Idec
      Dates: 
      2017-Present
    • Agency: 
      Novartis
      Dates: 
      2017-Present
    • Agency: 
      Genentech
      Dates: 
      2018-Present
    • Agency: 
      Optina
      Dates: 
      2018-Present
    • Agency: 
      Roche
      Dates: 
      2019

Damien Gallagher

  • Nothing to Disclose

Nathan Herrmann

  • Nothing to Disclose

Alex Kiss

  • Nothing to Disclose

Krista L. Lanctôt

  • Nothing to Disclose

Myuri Ruthirakuhan

  • Nothing to Disclose

Nicolaas Paul LG Verhoeff

  • Nothing to Disclose